Safety and Efficacy of Tisagenlecleucel Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) and No Evidence of Active Disease Following Bridging Chemotherapy in the JULIET Trial

CONCLUSIONSDespite no measurable disease remaining on preinfusion imaging, CAR-T cell expansion was observed in 7 of 8 pts in this setting, similar to the expansion in adults with active r/r DLBCL. Five of the 8 pts remained on study and were progression free > 12 months after infusion, which is higher than would be estimated with bridging chemotherapy alone. These data provide preliminary evidence that CAR-T cells provide clinical benefit in pts with r/r DLBCL who achieve CR with subsequent therapies and for design of CAR-T cell trials as consolidative therapy.DisclosuresBishop: United Healthcare: Employment; Seattle Genetics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Speakers Bureau; Juneau Therapeutics: Speakers Bureau; Novartis Pharmaceuticals Corporation: Speakers Bureau. Maziarz: Athersys, Inc.: Patents & Royalties; Kite Therapeutics: Honoraria; Juno Therapeutics: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Novartis Pharmaceuticals Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Waller: Celldex: Research Funding; Cambium Medical Technologies: Consultancy, Equity Ownership; Kalytera: Consultancy; Novartis Pharmaceuticals Corporation: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Other: Travel Expenses, EHA, Research Funding. del Corral: Novartis Pharmaceuticals Co...
Source: Blood - Category: Hematology Authors: Tags: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: Poster II Source Type: research